+Follow
曹环球
No personal profile
95
Follow
1
Followers
0
Topic
0
Badge
Posts
Hot
曹环球
2021-02-16
Okie
Joinn Laboratories begins its IPO today, with an entry fee of approximately HK$15,200.
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3572831909828511","uuid":"3572831909828511","gmtCreate":1609739061755,"gmtModify":1612234441408,"name":"曹环球","pinyin":"chqcaohuanqiu","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/ce307788b7898a4fbe10c5f18c696846","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":95,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-4","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Tiger Star","description":"Join the tiger community for 2000 days","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.06.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.72%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":382669879,"gmtCreate":1613442259491,"gmtModify":1704880487488,"author":{"id":"3572831909828511","authorId":"3572831909828511","name":"曹环球","avatar":"https://static.tigerbbs.com/ce307788b7898a4fbe10c5f18c696846","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572831909828511","idStr":"3572831909828511"},"themes":[],"title":"","htmlText":"Okie ","listText":"Okie ","text":"Okie","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/382669879","repostId":"2111004080","repostType":4,"repost":{"id":"2111004080","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1613431692,"share":"https://ttm.financial/m/news/2111004080?lang=en_US&edition=fundamental","pubTime":"2021-02-16 07:28","market":"hk","language":"zh","title":"Joinn Laboratories begins its IPO today, with an entry fee of approximately HK$15,200.","url":"https://stock-news.laohu8.com/highlight/detail?id=2111004080","media":"老虎资讯综合","summary":"2019年中国及全球药物非临床安全性合同研究组织市场的市场规模分别为4.16亿美元及48亿美元，分别约占2019年中国及全球医药合同研究组织市场的市场规模68亿美元及626亿美元的6.1%及7.7%。截至2020年9月30日止九个月，Biomere产生收益人民币1.58亿元，占公司总收益的25%并占同期公司绝大部分海外收益。基石投资者已同意在若干条件规限下按发售价认购以合共268亿美元可购买的一定数目的发售股份。","content":"<p>February 16th news,<a href=\"https://laohu8.com/S/603127\">Joinn Laboratories</a><a href=\"https://laohu8.com/S/06127\">$(06127)$</a>The company plans to issue 43.3248 million shares from February 16 to February 19, 2021. The Hong Kong public offering will account for 10%, the international offering will account for 90%, and there will be an over-allotment option of 15%. The H Shares are expected to commence trading in Hong Kong at 9:00 a.m. on February 26, 2021, at a price of HK$133-151 per share in lots of 100 shares.<img src=\"https://static.tigerbbs.com/79818d62c63fd4696523d37ce13c7f9d\" tg-width=\"717\" tg-height=\"587\" referrerpolicy=\"no-referrer\"><b>Subscription ladder:</b></p><p>Each lot contains 100 shares, with an entry fee of approximately HK$15,252.17.</p><p>The threshold for Group B is 40,000 shares, and the funds required for subscription are approximately HK$6,100,865.08.<img src=\"https://static.tigerbbs.com/1c06bc365ce512a6b3c155fc9ad62a13\" tg-width=\"738\" tg-height=\"445\" referrerpolicy=\"no-referrer\"></p><p>The company is a leading contract research organization focused on nonclinical safety evaluation of drugs and is expanding to provide comprehensive services covering drug discovery, preclinical and clinical trial stages in the drug development service chain. The company's non-clinical research refers to drug development research, which is not a clinical trial conducted on human subjects. These non-clinical studies cover all important stages of the drug development process, including drug discovery, pre-clinical and clinical trial stages.</p><p>The company is a contract research organization in China specializing in the pharmacology and toxicology research of new drugs. According to Frost & Sullivan, the company has now become the largest contract research organization in China for nonclinical safety evaluation of drugs, with a market share of 15.7% based on revenue in 2019. The market size of the China and global drug nonclinical safety contract research organization market in 2019 was US$416 million and US$4.8 billion, respectively, accounting for approximately 6.1% and 7.7% of the market size of the China and global pharmaceutical contract research organization market in 2019 of US$6.8 billion and US$62.6 billion, respectively. The company's A-shares have been listed on the Shanghai Stock Exchange since August 2017 (stock code: 603127).</p><p>The company is headquartered in Beijing and currently owns and operates two GLP certified facilities in China, located in Beijing and Suzhou, which are of strategic significance. According to Frost & Sullivan, the company is a leading contract research organization in China in terms of the size of its GLP-compliant facilities. The company's facilities in Beijing have a total gross floor area of approximately 11,600 square meters. The company's facilities in Suzhou have a total gross floor area of approximately 61,600 square meters, and the company plans to commence construction of approximately 20,000 square meters of additional laboratory and experimental model facilities in 2021.</p><p>To further expand its service capabilities and geographical coverage, the company is also planning to establish a drug safety evaluation center for innovative drugs and a central laboratory equipped with a bioanalytical service platform in Guangzhou, and to establish a GLP-compliant non-clinical research laboratory, experimental model breeding facility and clinical research central laboratory in Chongqing. The company expects the first phase of these facilities to be put into operation in 2023. In addition to its facilities in China, the company has been expanding its global footprint through organic growth and strategic acquisitions. In 2019, the company acquired Biomere, a professional contract research organization engaged in medical discovery located in Worcester, Massachusetts, which has an international customer base and a good reputation for customer service. For the nine months ended September 30, 2020, Biomere generated revenue of RMB158 million, accounting for 25% of the company's total revenue and the vast majority of the company's overseas revenue during the same period. Together with the facilities in Northern California that the Company plans to lease and upgrade in the near future, the Company aims to establish a strategic layout on the east and west coasts of the United States, with the Company's facilities in the United States located adjacent to two major life science centers in the United States.</p><p>During the track record period, the company achieved significant and robust growth in both its business and profitability. The Company's total revenue increased from RMB301 million in 2017 to RMB409 million in 2018 and further to RMB639 million in 2019, representing a CAGR of 45.7%. Profit for the year increased from RMB79.9 million in 2017 to RMB105 million in 2018 and further to RMB188 million in 2019, representing a CAGR of 53.2%.</p><p>The cornerstone investors have agreed, subject to certain conditions, to subscribe for a certain number of offer shares at the offer price, which can be purchased for a total of US$26.8 billion (approximately HK$2.078 billion). Assuming the offer price is HK$142 (i.e., the mid-point of the offer price range), the total number of offer shares to be subscribed by cornerstone investors will be 14.6318 million offer shares, representing approximately 33.8% of the number of H shares offered under the global offering and 5.4% of the company's total issued share capital immediately following the completion of the global offering.<img src=\"https://static.tigerbbs.com/4eeabccce9601f16c44ab0f537d674ae\" tg-width=\"632\" tg-height=\"633\" referrerpolicy=\"no-referrer\">The company's existing shareholders, Janchor Partners, Valliance Fund, CPE Fund, and ICBCCS (held on behalf of the China Structural Adjustment Fund), have been approved to participate in the cornerstone placement. In addition, there are a total of 10 cornerstone investors, including Lake Bleu Prime, managed by Clear Pool Capital (Hong Kong) Limited; OrbiMed Fund; China Structural Adjustment Fund; CPE Fund managed by Yuanfeng Fund; Redwood Capital China Growth; Janchor Partners Pan-Asian Master Fund; CRF; Carmignac Fund; Octagon Capital; Valliance Fund.</p><p>Assuming an offer price of HK$142.00, the net proceeds would be HK$5.91 billion. Approximately 16% will be used to renovate existing equipment and facilities, establish new experimental model breeding and inventory facilities, and hire experienced professionals to increase the non-clinical research capacity of the company's Suzhou facility. Approximately 10% strengthen the company's U.S. business to meet the growing customer demand for the services provided by Biomere. Approximately 39% will be used to build new facilities in Guangzhou and Chongqing, hire experienced professionals, and develop cutting-edge technologies to further expand the company's facility network and service capabilities in China. Approximately 5% will expand and deepen the company's integrated contract research organization services, with a particular focus on further expanding the company's clinical trials and related services. Approximately 20% will be funded by suitable contract research organizations focused on non-clinical research, contract research organizations focused on clinical trials, and potential acquisitions of experimental model manufacturing facilities in China and overseas, in order to further implement the company's strategy of broadening the scope of comprehensive services in the drug development value chain and expanding its overseas presence within the next one to three years. Approximately 10% will be used for working capital and general corporate purposes.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Joinn Laboratories begins its IPO today, with an entry fee of approximately HK$15,200.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJoinn Laboratories begins its IPO today, with an entry fee of approximately HK$15,200.\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-02-16 07:28</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>February 16th news,<a href=\"https://laohu8.com/S/603127\">Joinn Laboratories</a><a href=\"https://laohu8.com/S/06127\">$(06127)$</a>The company plans to issue 43.3248 million shares from February 16 to February 19, 2021. The Hong Kong public offering will account for 10%, the international offering will account for 90%, and there will be an over-allotment option of 15%. The H Shares are expected to commence trading in Hong Kong at 9:00 a.m. on February 26, 2021, at a price of HK$133-151 per share in lots of 100 shares.<img src=\"https://static.tigerbbs.com/79818d62c63fd4696523d37ce13c7f9d\" tg-width=\"717\" tg-height=\"587\" referrerpolicy=\"no-referrer\"><b>Subscription ladder:</b></p><p>Each lot contains 100 shares, with an entry fee of approximately HK$15,252.17.</p><p>The threshold for Group B is 40,000 shares, and the funds required for subscription are approximately HK$6,100,865.08.<img src=\"https://static.tigerbbs.com/1c06bc365ce512a6b3c155fc9ad62a13\" tg-width=\"738\" tg-height=\"445\" referrerpolicy=\"no-referrer\"></p><p>The company is a leading contract research organization focused on nonclinical safety evaluation of drugs and is expanding to provide comprehensive services covering drug discovery, preclinical and clinical trial stages in the drug development service chain. The company's non-clinical research refers to drug development research, which is not a clinical trial conducted on human subjects. These non-clinical studies cover all important stages of the drug development process, including drug discovery, pre-clinical and clinical trial stages.</p><p>The company is a contract research organization in China specializing in the pharmacology and toxicology research of new drugs. According to Frost & Sullivan, the company has now become the largest contract research organization in China for nonclinical safety evaluation of drugs, with a market share of 15.7% based on revenue in 2019. The market size of the China and global drug nonclinical safety contract research organization market in 2019 was US$416 million and US$4.8 billion, respectively, accounting for approximately 6.1% and 7.7% of the market size of the China and global pharmaceutical contract research organization market in 2019 of US$6.8 billion and US$62.6 billion, respectively. The company's A-shares have been listed on the Shanghai Stock Exchange since August 2017 (stock code: 603127).</p><p>The company is headquartered in Beijing and currently owns and operates two GLP certified facilities in China, located in Beijing and Suzhou, which are of strategic significance. According to Frost & Sullivan, the company is a leading contract research organization in China in terms of the size of its GLP-compliant facilities. The company's facilities in Beijing have a total gross floor area of approximately 11,600 square meters. The company's facilities in Suzhou have a total gross floor area of approximately 61,600 square meters, and the company plans to commence construction of approximately 20,000 square meters of additional laboratory and experimental model facilities in 2021.</p><p>To further expand its service capabilities and geographical coverage, the company is also planning to establish a drug safety evaluation center for innovative drugs and a central laboratory equipped with a bioanalytical service platform in Guangzhou, and to establish a GLP-compliant non-clinical research laboratory, experimental model breeding facility and clinical research central laboratory in Chongqing. The company expects the first phase of these facilities to be put into operation in 2023. In addition to its facilities in China, the company has been expanding its global footprint through organic growth and strategic acquisitions. In 2019, the company acquired Biomere, a professional contract research organization engaged in medical discovery located in Worcester, Massachusetts, which has an international customer base and a good reputation for customer service. For the nine months ended September 30, 2020, Biomere generated revenue of RMB158 million, accounting for 25% of the company's total revenue and the vast majority of the company's overseas revenue during the same period. Together with the facilities in Northern California that the Company plans to lease and upgrade in the near future, the Company aims to establish a strategic layout on the east and west coasts of the United States, with the Company's facilities in the United States located adjacent to two major life science centers in the United States.</p><p>During the track record period, the company achieved significant and robust growth in both its business and profitability. The Company's total revenue increased from RMB301 million in 2017 to RMB409 million in 2018 and further to RMB639 million in 2019, representing a CAGR of 45.7%. Profit for the year increased from RMB79.9 million in 2017 to RMB105 million in 2018 and further to RMB188 million in 2019, representing a CAGR of 53.2%.</p><p>The cornerstone investors have agreed, subject to certain conditions, to subscribe for a certain number of offer shares at the offer price, which can be purchased for a total of US$26.8 billion (approximately HK$2.078 billion). Assuming the offer price is HK$142 (i.e., the mid-point of the offer price range), the total number of offer shares to be subscribed by cornerstone investors will be 14.6318 million offer shares, representing approximately 33.8% of the number of H shares offered under the global offering and 5.4% of the company's total issued share capital immediately following the completion of the global offering.<img src=\"https://static.tigerbbs.com/4eeabccce9601f16c44ab0f537d674ae\" tg-width=\"632\" tg-height=\"633\" referrerpolicy=\"no-referrer\">The company's existing shareholders, Janchor Partners, Valliance Fund, CPE Fund, and ICBCCS (held on behalf of the China Structural Adjustment Fund), have been approved to participate in the cornerstone placement. In addition, there are a total of 10 cornerstone investors, including Lake Bleu Prime, managed by Clear Pool Capital (Hong Kong) Limited; OrbiMed Fund; China Structural Adjustment Fund; CPE Fund managed by Yuanfeng Fund; Redwood Capital China Growth; Janchor Partners Pan-Asian Master Fund; CRF; Carmignac Fund; Octagon Capital; Valliance Fund.</p><p>Assuming an offer price of HK$142.00, the net proceeds would be HK$5.91 billion. Approximately 16% will be used to renovate existing equipment and facilities, establish new experimental model breeding and inventory facilities, and hire experienced professionals to increase the non-clinical research capacity of the company's Suzhou facility. Approximately 10% strengthen the company's U.S. business to meet the growing customer demand for the services provided by Biomere. Approximately 39% will be used to build new facilities in Guangzhou and Chongqing, hire experienced professionals, and develop cutting-edge technologies to further expand the company's facility network and service capabilities in China. Approximately 5% will expand and deepen the company's integrated contract research organization services, with a particular focus on further expanding the company's clinical trials and related services. Approximately 20% will be funded by suitable contract research organizations focused on non-clinical research, contract research organizations focused on clinical trials, and potential acquisitions of experimental model manufacturing facilities in China and overseas, in order to further implement the company's strategy of broadening the scope of comprehensive services in the drug development value chain and expanding its overseas presence within the next one to three years. Approximately 10% will be used for working capital and general corporate purposes.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","relate_stocks":{"603127":"昭衍新药","000860.SH":"结构调整","06127":"昭衍新药"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2111004080","content_text":"2月16日消息，昭衍新药$(06127)$于2021年2月16日-2月19日招股，公司拟发行4332.48万股，香港公开发售占10%，国际发售占90%，另有15%超额配股权。每股133-151港元，每手100股，预期H股将在香港于2021年2月26日上午九时正开始买卖。申购阶梯：每手100股，入场费约15252.17港元。乙组门槛为4万股，申购所需资金约6100865.08港元。公司是一家专注于药物非临床安全性评价的领先合同研究组织，正扩展以提供涵盖药物研发服务链上药物发现、临床前和临床试验阶段的综合服务。公司的非临床研究指药物研发研究，并非以人为受试对象进行的临床试验。该等非临床研究涵盖药物研发过程的所有重要阶段，包括药物发现、临床前及临床试验阶段。公司是国内专门从事新药药理毒理学研究的合同研究组织，根据弗若斯特沙利文的资料，现在公司已成为国内最大的药物非临床安全性评价合同研究组织，按2019年的收益计，市场份额为15.7%。2019年中国及全球药物非临床安全性合同研究组织市场的市场规模分别为4.16亿美元及48亿美元，分别约占2019年中国及全球医药合同研究组织市场的市场规模68亿美元及626亿美元的6.1%及7.7%。公司A股自 2017年8月起已于上海证券交易所上市(股票代码：603127)。公司的总部位于北京，目前在国内拥有及经营两家GLP认证设施，位于北京及苏州，具有战略意义。根据弗若斯特沙利文的资料，按符合GLP设施的规模计，公司是中国领先的合同研究组织。公司位于北京的设施总建筑面积约11,600平方米。公司位于苏州的设施总建筑面积约61,600平方米，且公司计划于2021年开工建设约20,000平方米的额外实验室及实验模型设施。为进一步扩大服务能力及地理覆盖范围，公司亦正计划在广州建立一个创新药的药物安全评价中心及配备生物分析服务相关平台的中央实验室，及在重庆建立符合GLP的非临床研究实验室、实验模型繁殖设施及临床研究中央实验室。公司预计该等设施一期将于2023年投入运营。除在中国的设施外，公司一直透过内生增长及策略性收购扩阔公司的全球版图。公司于2019年收购Biomere，一个位于马萨诸塞州伍斯特市从事医药发现的专业合同研究组织，其拥有国际客户基础且在客户服务方面拥有良好声誉。截至2020年9月30日止九个月，Biomere产生收益人民币1.58亿元，占公司总收益的25%并占同期公司绝大部分海外收益。连同公司计划近期租赁及升级的位于北加利福尼亚州的设施，公司旨在于美国东西海岸确立具有战略意义的布局，使公司的各美国设施所处位置毗邻美国两大着名生命科学中心。于往绩记录期，公司的业务及盈利能力双双实现大规模有力增长。公司的总收益由2017年的人民币3.01亿元增至2018年的人民币4.09亿元，并进一步增至2019 年的人民币6.39亿元，复合年增长率为45.7%。年内利润由2017年的人民币7990万元增至2018年的人民币1.05亿元，并进一步增至2019年的人民币1.88亿元，复合年增长率为53.2%。基石投资者已同意在若干条件规限下按发售价认购以合共268亿美元(约20.78亿港元)可购买的一定数目的发售股份。假设发售价为142港元(即发售价范围的中位数)，则基石投资者将予认购的发售股份总数将为1463.18万股发售股份，约占根据全球发售提呈发售的H股数目的33.8%及紧随全球发售完成后公司已发行股本总额的5.4%。公司的现有股东Janchor Partners、Valliance Fund、CPE Fund及ICBCCS(代表中国结构调整基金持有)已获准参与基石配售。此外，基石投资者总共10个，包括由清池资本(香港)有限公司管理的Lake Bleu Prime;OrbiMed基金;中国结构调整基金;由源峰基金管理的CPE Fund;Sequoia Capital China Growth;Janchor Partners Pan-Asian Master Fund;CRF;Carmignac基金;Octagon Capital;Valliance Fund。假设发售价为142.00港元，净筹59.1亿港元。约16%将用于翻新现有设备及设施，建立新的实验模型繁殖及存货设施及雇佣经验丰富的专业人员，以提高公司苏州设施的非临床研究产能。约10%增强公司的美国业务以迎合客户对Biomere所提供服务日益增长的需求。约39%将用于在广州及重庆建设新设施，雇佣经验丰富的专业人员，及发展尖端技术，进一步扩大公司于中国的设施网络及服务能力。约5%拓展及深化公司的综合合同研究组织服务，特别着重于进一步扩展公司的临床试验及相关服务。约20%为合适的专注于非临床研究的合同研究组织，专注于临床试验的合同研究组织及中国及海外的实验模型生产设施的潜在收购提供资金，以于未来一至三年内进一步实施公司拓宽药物研发价值链上的综合服务范围并拓展海外布局的策略。约10%将用于营运资金及一般企业用途。","news_type":1,"symbols_score_info":{"603127":0.9,"06127":0.9,"000860.SH":0.9}},"isVote":1,"tweetType":1,"viewCount":3630,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":382669879,"gmtCreate":1613442259491,"gmtModify":1704880487488,"author":{"id":"3572831909828511","authorId":"3572831909828511","name":"曹环球","avatar":"https://static.tigerbbs.com/ce307788b7898a4fbe10c5f18c696846","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572831909828511","idStr":"3572831909828511"},"themes":[],"title":"","htmlText":"Okie ","listText":"Okie ","text":"Okie","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/382669879","repostId":"2111004080","repostType":4,"repost":{"id":"2111004080","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1613431692,"share":"https://ttm.financial/m/news/2111004080?lang=en_US&edition=fundamental","pubTime":"2021-02-16 07:28","market":"hk","language":"zh","title":"Joinn Laboratories begins its IPO today, with an entry fee of approximately HK$15,200.","url":"https://stock-news.laohu8.com/highlight/detail?id=2111004080","media":"老虎资讯综合","summary":"2019年中国及全球药物非临床安全性合同研究组织市场的市场规模分别为4.16亿美元及48亿美元，分别约占2019年中国及全球医药合同研究组织市场的市场规模68亿美元及626亿美元的6.1%及7.7%。截至2020年9月30日止九个月，Biomere产生收益人民币1.58亿元，占公司总收益的25%并占同期公司绝大部分海外收益。基石投资者已同意在若干条件规限下按发售价认购以合共268亿美元可购买的一定数目的发售股份。","content":"<p>February 16th news,<a href=\"https://laohu8.com/S/603127\">Joinn Laboratories</a><a href=\"https://laohu8.com/S/06127\">$(06127)$</a>The company plans to issue 43.3248 million shares from February 16 to February 19, 2021. The Hong Kong public offering will account for 10%, the international offering will account for 90%, and there will be an over-allotment option of 15%. The H Shares are expected to commence trading in Hong Kong at 9:00 a.m. on February 26, 2021, at a price of HK$133-151 per share in lots of 100 shares.<img src=\"https://static.tigerbbs.com/79818d62c63fd4696523d37ce13c7f9d\" tg-width=\"717\" tg-height=\"587\" referrerpolicy=\"no-referrer\"><b>Subscription ladder:</b></p><p>Each lot contains 100 shares, with an entry fee of approximately HK$15,252.17.</p><p>The threshold for Group B is 40,000 shares, and the funds required for subscription are approximately HK$6,100,865.08.<img src=\"https://static.tigerbbs.com/1c06bc365ce512a6b3c155fc9ad62a13\" tg-width=\"738\" tg-height=\"445\" referrerpolicy=\"no-referrer\"></p><p>The company is a leading contract research organization focused on nonclinical safety evaluation of drugs and is expanding to provide comprehensive services covering drug discovery, preclinical and clinical trial stages in the drug development service chain. The company's non-clinical research refers to drug development research, which is not a clinical trial conducted on human subjects. These non-clinical studies cover all important stages of the drug development process, including drug discovery, pre-clinical and clinical trial stages.</p><p>The company is a contract research organization in China specializing in the pharmacology and toxicology research of new drugs. According to Frost & Sullivan, the company has now become the largest contract research organization in China for nonclinical safety evaluation of drugs, with a market share of 15.7% based on revenue in 2019. The market size of the China and global drug nonclinical safety contract research organization market in 2019 was US$416 million and US$4.8 billion, respectively, accounting for approximately 6.1% and 7.7% of the market size of the China and global pharmaceutical contract research organization market in 2019 of US$6.8 billion and US$62.6 billion, respectively. The company's A-shares have been listed on the Shanghai Stock Exchange since August 2017 (stock code: 603127).</p><p>The company is headquartered in Beijing and currently owns and operates two GLP certified facilities in China, located in Beijing and Suzhou, which are of strategic significance. According to Frost & Sullivan, the company is a leading contract research organization in China in terms of the size of its GLP-compliant facilities. The company's facilities in Beijing have a total gross floor area of approximately 11,600 square meters. The company's facilities in Suzhou have a total gross floor area of approximately 61,600 square meters, and the company plans to commence construction of approximately 20,000 square meters of additional laboratory and experimental model facilities in 2021.</p><p>To further expand its service capabilities and geographical coverage, the company is also planning to establish a drug safety evaluation center for innovative drugs and a central laboratory equipped with a bioanalytical service platform in Guangzhou, and to establish a GLP-compliant non-clinical research laboratory, experimental model breeding facility and clinical research central laboratory in Chongqing. The company expects the first phase of these facilities to be put into operation in 2023. In addition to its facilities in China, the company has been expanding its global footprint through organic growth and strategic acquisitions. In 2019, the company acquired Biomere, a professional contract research organization engaged in medical discovery located in Worcester, Massachusetts, which has an international customer base and a good reputation for customer service. For the nine months ended September 30, 2020, Biomere generated revenue of RMB158 million, accounting for 25% of the company's total revenue and the vast majority of the company's overseas revenue during the same period. Together with the facilities in Northern California that the Company plans to lease and upgrade in the near future, the Company aims to establish a strategic layout on the east and west coasts of the United States, with the Company's facilities in the United States located adjacent to two major life science centers in the United States.</p><p>During the track record period, the company achieved significant and robust growth in both its business and profitability. The Company's total revenue increased from RMB301 million in 2017 to RMB409 million in 2018 and further to RMB639 million in 2019, representing a CAGR of 45.7%. Profit for the year increased from RMB79.9 million in 2017 to RMB105 million in 2018 and further to RMB188 million in 2019, representing a CAGR of 53.2%.</p><p>The cornerstone investors have agreed, subject to certain conditions, to subscribe for a certain number of offer shares at the offer price, which can be purchased for a total of US$26.8 billion (approximately HK$2.078 billion). Assuming the offer price is HK$142 (i.e., the mid-point of the offer price range), the total number of offer shares to be subscribed by cornerstone investors will be 14.6318 million offer shares, representing approximately 33.8% of the number of H shares offered under the global offering and 5.4% of the company's total issued share capital immediately following the completion of the global offering.<img src=\"https://static.tigerbbs.com/4eeabccce9601f16c44ab0f537d674ae\" tg-width=\"632\" tg-height=\"633\" referrerpolicy=\"no-referrer\">The company's existing shareholders, Janchor Partners, Valliance Fund, CPE Fund, and ICBCCS (held on behalf of the China Structural Adjustment Fund), have been approved to participate in the cornerstone placement. In addition, there are a total of 10 cornerstone investors, including Lake Bleu Prime, managed by Clear Pool Capital (Hong Kong) Limited; OrbiMed Fund; China Structural Adjustment Fund; CPE Fund managed by Yuanfeng Fund; Redwood Capital China Growth; Janchor Partners Pan-Asian Master Fund; CRF; Carmignac Fund; Octagon Capital; Valliance Fund.</p><p>Assuming an offer price of HK$142.00, the net proceeds would be HK$5.91 billion. Approximately 16% will be used to renovate existing equipment and facilities, establish new experimental model breeding and inventory facilities, and hire experienced professionals to increase the non-clinical research capacity of the company's Suzhou facility. Approximately 10% strengthen the company's U.S. business to meet the growing customer demand for the services provided by Biomere. Approximately 39% will be used to build new facilities in Guangzhou and Chongqing, hire experienced professionals, and develop cutting-edge technologies to further expand the company's facility network and service capabilities in China. Approximately 5% will expand and deepen the company's integrated contract research organization services, with a particular focus on further expanding the company's clinical trials and related services. Approximately 20% will be funded by suitable contract research organizations focused on non-clinical research, contract research organizations focused on clinical trials, and potential acquisitions of experimental model manufacturing facilities in China and overseas, in order to further implement the company's strategy of broadening the scope of comprehensive services in the drug development value chain and expanding its overseas presence within the next one to three years. Approximately 10% will be used for working capital and general corporate purposes.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Joinn Laboratories begins its IPO today, with an entry fee of approximately HK$15,200.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJoinn Laboratories begins its IPO today, with an entry fee of approximately HK$15,200.\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-02-16 07:28</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>February 16th news,<a href=\"https://laohu8.com/S/603127\">Joinn Laboratories</a><a href=\"https://laohu8.com/S/06127\">$(06127)$</a>The company plans to issue 43.3248 million shares from February 16 to February 19, 2021. The Hong Kong public offering will account for 10%, the international offering will account for 90%, and there will be an over-allotment option of 15%. The H Shares are expected to commence trading in Hong Kong at 9:00 a.m. on February 26, 2021, at a price of HK$133-151 per share in lots of 100 shares.<img src=\"https://static.tigerbbs.com/79818d62c63fd4696523d37ce13c7f9d\" tg-width=\"717\" tg-height=\"587\" referrerpolicy=\"no-referrer\"><b>Subscription ladder:</b></p><p>Each lot contains 100 shares, with an entry fee of approximately HK$15,252.17.</p><p>The threshold for Group B is 40,000 shares, and the funds required for subscription are approximately HK$6,100,865.08.<img src=\"https://static.tigerbbs.com/1c06bc365ce512a6b3c155fc9ad62a13\" tg-width=\"738\" tg-height=\"445\" referrerpolicy=\"no-referrer\"></p><p>The company is a leading contract research organization focused on nonclinical safety evaluation of drugs and is expanding to provide comprehensive services covering drug discovery, preclinical and clinical trial stages in the drug development service chain. The company's non-clinical research refers to drug development research, which is not a clinical trial conducted on human subjects. These non-clinical studies cover all important stages of the drug development process, including drug discovery, pre-clinical and clinical trial stages.</p><p>The company is a contract research organization in China specializing in the pharmacology and toxicology research of new drugs. According to Frost & Sullivan, the company has now become the largest contract research organization in China for nonclinical safety evaluation of drugs, with a market share of 15.7% based on revenue in 2019. The market size of the China and global drug nonclinical safety contract research organization market in 2019 was US$416 million and US$4.8 billion, respectively, accounting for approximately 6.1% and 7.7% of the market size of the China and global pharmaceutical contract research organization market in 2019 of US$6.8 billion and US$62.6 billion, respectively. The company's A-shares have been listed on the Shanghai Stock Exchange since August 2017 (stock code: 603127).</p><p>The company is headquartered in Beijing and currently owns and operates two GLP certified facilities in China, located in Beijing and Suzhou, which are of strategic significance. According to Frost & Sullivan, the company is a leading contract research organization in China in terms of the size of its GLP-compliant facilities. The company's facilities in Beijing have a total gross floor area of approximately 11,600 square meters. The company's facilities in Suzhou have a total gross floor area of approximately 61,600 square meters, and the company plans to commence construction of approximately 20,000 square meters of additional laboratory and experimental model facilities in 2021.</p><p>To further expand its service capabilities and geographical coverage, the company is also planning to establish a drug safety evaluation center for innovative drugs and a central laboratory equipped with a bioanalytical service platform in Guangzhou, and to establish a GLP-compliant non-clinical research laboratory, experimental model breeding facility and clinical research central laboratory in Chongqing. The company expects the first phase of these facilities to be put into operation in 2023. In addition to its facilities in China, the company has been expanding its global footprint through organic growth and strategic acquisitions. In 2019, the company acquired Biomere, a professional contract research organization engaged in medical discovery located in Worcester, Massachusetts, which has an international customer base and a good reputation for customer service. For the nine months ended September 30, 2020, Biomere generated revenue of RMB158 million, accounting for 25% of the company's total revenue and the vast majority of the company's overseas revenue during the same period. Together with the facilities in Northern California that the Company plans to lease and upgrade in the near future, the Company aims to establish a strategic layout on the east and west coasts of the United States, with the Company's facilities in the United States located adjacent to two major life science centers in the United States.</p><p>During the track record period, the company achieved significant and robust growth in both its business and profitability. The Company's total revenue increased from RMB301 million in 2017 to RMB409 million in 2018 and further to RMB639 million in 2019, representing a CAGR of 45.7%. Profit for the year increased from RMB79.9 million in 2017 to RMB105 million in 2018 and further to RMB188 million in 2019, representing a CAGR of 53.2%.</p><p>The cornerstone investors have agreed, subject to certain conditions, to subscribe for a certain number of offer shares at the offer price, which can be purchased for a total of US$26.8 billion (approximately HK$2.078 billion). Assuming the offer price is HK$142 (i.e., the mid-point of the offer price range), the total number of offer shares to be subscribed by cornerstone investors will be 14.6318 million offer shares, representing approximately 33.8% of the number of H shares offered under the global offering and 5.4% of the company's total issued share capital immediately following the completion of the global offering.<img src=\"https://static.tigerbbs.com/4eeabccce9601f16c44ab0f537d674ae\" tg-width=\"632\" tg-height=\"633\" referrerpolicy=\"no-referrer\">The company's existing shareholders, Janchor Partners, Valliance Fund, CPE Fund, and ICBCCS (held on behalf of the China Structural Adjustment Fund), have been approved to participate in the cornerstone placement. In addition, there are a total of 10 cornerstone investors, including Lake Bleu Prime, managed by Clear Pool Capital (Hong Kong) Limited; OrbiMed Fund; China Structural Adjustment Fund; CPE Fund managed by Yuanfeng Fund; Redwood Capital China Growth; Janchor Partners Pan-Asian Master Fund; CRF; Carmignac Fund; Octagon Capital; Valliance Fund.</p><p>Assuming an offer price of HK$142.00, the net proceeds would be HK$5.91 billion. Approximately 16% will be used to renovate existing equipment and facilities, establish new experimental model breeding and inventory facilities, and hire experienced professionals to increase the non-clinical research capacity of the company's Suzhou facility. Approximately 10% strengthen the company's U.S. business to meet the growing customer demand for the services provided by Biomere. Approximately 39% will be used to build new facilities in Guangzhou and Chongqing, hire experienced professionals, and develop cutting-edge technologies to further expand the company's facility network and service capabilities in China. Approximately 5% will expand and deepen the company's integrated contract research organization services, with a particular focus on further expanding the company's clinical trials and related services. Approximately 20% will be funded by suitable contract research organizations focused on non-clinical research, contract research organizations focused on clinical trials, and potential acquisitions of experimental model manufacturing facilities in China and overseas, in order to further implement the company's strategy of broadening the scope of comprehensive services in the drug development value chain and expanding its overseas presence within the next one to three years. Approximately 10% will be used for working capital and general corporate purposes.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","relate_stocks":{"603127":"昭衍新药","000860.SH":"结构调整","06127":"昭衍新药"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2111004080","content_text":"2月16日消息，昭衍新药$(06127)$于2021年2月16日-2月19日招股，公司拟发行4332.48万股，香港公开发售占10%，国际发售占90%，另有15%超额配股权。每股133-151港元，每手100股，预期H股将在香港于2021年2月26日上午九时正开始买卖。申购阶梯：每手100股，入场费约15252.17港元。乙组门槛为4万股，申购所需资金约6100865.08港元。公司是一家专注于药物非临床安全性评价的领先合同研究组织，正扩展以提供涵盖药物研发服务链上药物发现、临床前和临床试验阶段的综合服务。公司的非临床研究指药物研发研究，并非以人为受试对象进行的临床试验。该等非临床研究涵盖药物研发过程的所有重要阶段，包括药物发现、临床前及临床试验阶段。公司是国内专门从事新药药理毒理学研究的合同研究组织，根据弗若斯特沙利文的资料，现在公司已成为国内最大的药物非临床安全性评价合同研究组织，按2019年的收益计，市场份额为15.7%。2019年中国及全球药物非临床安全性合同研究组织市场的市场规模分别为4.16亿美元及48亿美元，分别约占2019年中国及全球医药合同研究组织市场的市场规模68亿美元及626亿美元的6.1%及7.7%。公司A股自 2017年8月起已于上海证券交易所上市(股票代码：603127)。公司的总部位于北京，目前在国内拥有及经营两家GLP认证设施，位于北京及苏州，具有战略意义。根据弗若斯特沙利文的资料，按符合GLP设施的规模计，公司是中国领先的合同研究组织。公司位于北京的设施总建筑面积约11,600平方米。公司位于苏州的设施总建筑面积约61,600平方米，且公司计划于2021年开工建设约20,000平方米的额外实验室及实验模型设施。为进一步扩大服务能力及地理覆盖范围，公司亦正计划在广州建立一个创新药的药物安全评价中心及配备生物分析服务相关平台的中央实验室，及在重庆建立符合GLP的非临床研究实验室、实验模型繁殖设施及临床研究中央实验室。公司预计该等设施一期将于2023年投入运营。除在中国的设施外，公司一直透过内生增长及策略性收购扩阔公司的全球版图。公司于2019年收购Biomere，一个位于马萨诸塞州伍斯特市从事医药发现的专业合同研究组织，其拥有国际客户基础且在客户服务方面拥有良好声誉。截至2020年9月30日止九个月，Biomere产生收益人民币1.58亿元，占公司总收益的25%并占同期公司绝大部分海外收益。连同公司计划近期租赁及升级的位于北加利福尼亚州的设施，公司旨在于美国东西海岸确立具有战略意义的布局，使公司的各美国设施所处位置毗邻美国两大着名生命科学中心。于往绩记录期，公司的业务及盈利能力双双实现大规模有力增长。公司的总收益由2017年的人民币3.01亿元增至2018年的人民币4.09亿元，并进一步增至2019 年的人民币6.39亿元，复合年增长率为45.7%。年内利润由2017年的人民币7990万元增至2018年的人民币1.05亿元，并进一步增至2019年的人民币1.88亿元，复合年增长率为53.2%。基石投资者已同意在若干条件规限下按发售价认购以合共268亿美元(约20.78亿港元)可购买的一定数目的发售股份。假设发售价为142港元(即发售价范围的中位数)，则基石投资者将予认购的发售股份总数将为1463.18万股发售股份，约占根据全球发售提呈发售的H股数目的33.8%及紧随全球发售完成后公司已发行股本总额的5.4%。公司的现有股东Janchor Partners、Valliance Fund、CPE Fund及ICBCCS(代表中国结构调整基金持有)已获准参与基石配售。此外，基石投资者总共10个，包括由清池资本(香港)有限公司管理的Lake Bleu Prime;OrbiMed基金;中国结构调整基金;由源峰基金管理的CPE Fund;Sequoia Capital China Growth;Janchor Partners Pan-Asian Master Fund;CRF;Carmignac基金;Octagon Capital;Valliance Fund。假设发售价为142.00港元，净筹59.1亿港元。约16%将用于翻新现有设备及设施，建立新的实验模型繁殖及存货设施及雇佣经验丰富的专业人员，以提高公司苏州设施的非临床研究产能。约10%增强公司的美国业务以迎合客户对Biomere所提供服务日益增长的需求。约39%将用于在广州及重庆建设新设施，雇佣经验丰富的专业人员，及发展尖端技术，进一步扩大公司于中国的设施网络及服务能力。约5%拓展及深化公司的综合合同研究组织服务，特别着重于进一步扩展公司的临床试验及相关服务。约20%为合适的专注于非临床研究的合同研究组织，专注于临床试验的合同研究组织及中国及海外的实验模型生产设施的潜在收购提供资金，以于未来一至三年内进一步实施公司拓宽药物研发价值链上的综合服务范围并拓展海外布局的策略。约10%将用于营运资金及一般企业用途。","news_type":1,"symbols_score_info":{"603127":0.9,"06127":0.9,"000860.SH":0.9}},"isVote":1,"tweetType":1,"viewCount":3630,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
